04 February 2025
via Zoom
Draft Agenda
The meeting will take place as a meeting via Zoom, a secure web conferencing tool.
This meeting will run from 9:00am to 1:00pm, although timings may be subject to change. You will receive your invitation and joining link for each topic you have registered for once registration closes. You will be able to join at the time stated on your invite.
Please note that this agenda is draft agenda and is subject to change before the meeting.
- Welcome and introduction to format of meeting – Part 2 only (closed session)
- Minutes from the last meeting held on Tuesday 7 January 2025 – Part 2 only (closed session)
- Declarations of interest – Part 2 only (closed session)
- Appraisal of pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer [ID6381]
4.1. Introduction by the Chair, Radha Todd Part 2 only (closed session
4.2. Declaration of interests Part 2 only (closed session
4.3. Presentation by the lead team Part 2 only (closed session
4.4 Agreement on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG)
Part 2 only (closed session)
Please note that Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer has not yet received regulatory approval for this indication so this committee discussion will be held in private (Part 2 closed session only)
To print this agenda, please right click and select ‘Print’ from the menu.
Should you have any queries regarding observing this meeting, please contact Leah Murphy.
- Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
Date and time of next meeting
The next meeting will take place on Tuesday 4 March at 9am via Zoom.
Please note all timings are approximate.